Laura G. Eichorn - 16 Aug 2022 Form 4 Insider Report for Imago BioSciences, Inc.

Role: Chief Financial Officer
Signature: /s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn
Issuer symbol: N/A
Transactions as of: 16 Aug 2022
Net transactions value: -$15,384
Form type: 4
Filing time: 18 Aug 2022, 17:50:01 UTC
Previous filing: 21 Jul 2022
Next filing: 24 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMGO	Common Stock	Options Exercise	$1,343	+533	+0.26%	$2.52^*	208,270	16 Aug 2022	Direct	F1
transaction	IMGO	Common Stock	Sale	$10,394	-533	-0.26%	$19.50	207,737	16 Aug 2022	Direct	F1
transaction	IMGO	Common Stock	Options Exercise	$940	+373	+0.18%	$2.52^*	208,110	17 Aug 2022	Direct	F1
transaction	IMGO	Common Stock	Sale	$7,274	-373	-0.18%	$19.50	207,737	17 Aug 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMGO	Stock Option (Right to Buy)	Options Exercise	$0	-533	-0.53%	$0.000000	100,423	16 Aug 2022	Common Stock	533	$2.52	Direct	F1
transaction	IMGO	Stock Option (Right to Buy)	Options Exercise	$0	-373	-0.37%	$0.000000	100,050	17 Aug 2022	Common Stock	373	$2.52	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The transaction was executed in multiple trades in prices ranging from $19.50 to $19.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Content

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

The transaction was executed in multiple trades in prices ranging from $19.50 to $19.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Chief Financial Officer